Reviva Pharmaceuticals
Biotechnology, Stevens Creek BLVD Ste 100, Cupertino, , 95014, California, 19925, United States, 11-50 Employees
Phone Number: +14*********
Who is REVIVA PHARMACEUTICALS
NASDAQ: RVPH Reviva Pharmaceuticals, Inc., (Reviva) headquartered in Santa Clara, California, is a publicly traded, late-stage clinical development pharmaceutical company. Reviva is devel...
Read More
-
Headquarters: 19925 Stevens Creek BLVD Ste 100, Cupertino, California, 95014, United States
-
Date Founded: 2020
-
Employees: 11-50
-
Revenue: $1 Million to $5 Million
-
Active Tech Stack: See technologies
-
CEO:
Laxminarayan Bhat
Email
Phone
Industry: Biotechnology
SIC Code: 2834
|
NAICS Code: 325412 |
Show More
Does something look wrong? Fix it. | View contact records from REVIVA PHARMACEUTICALS
Reviva Pharmaceuticals Org Chart and Mapping
Sign in to CIENCE GO Data to uncover contact details
Free credits every month
Frequently Asked Questions Regarding Reviva Pharmaceuticals
Answer: Reviva Pharmaceuticals's headquarters are located at Stevens Creek BLVD Ste 100, Cupertino, , 95014, California, 19925, United States
Answer: Reviva Pharmaceuticals's phone number is +14*********
Answer: Reviva Pharmaceuticals's official website is https://revivapharma.com
Answer: Reviva Pharmaceuticals's revenue is $1 Million to $5 Million
Answer: Reviva Pharmaceuticals's SIC: 2834
Answer: Reviva Pharmaceuticals's NAICS: 325412
Answer: Reviva Pharmaceuticals has 11-50 employees
Answer: Reviva Pharmaceuticals is in Biotechnology
Answer: Reviva Pharmaceuticals contact info: Phone number: +14********* Website: https://revivapharma.com
Answer: NASDAQ: RVPH Reviva Pharmaceuticals, Inc., (Reviva) headquartered in Santa Clara, California, is a publicly traded, late-stage clinical development pharmaceutical company. Reviva is developing a portfolio of internally discovered next generation innovative therapies using chemical genomic driven approaches and proprietary technologies that addresses unmet medical needs in the areas of central nervous system (CNS), cardiovascular, metabolic and inflammatory diseases. The leadership and management team is comprised of highly successful and experienced professionals from the pharmaceutical industry and have a demonstrated track record of taking drugs through the development process to the global market. Speed without sacrificing quality is one of the hallmarks of Revivas product development model. The company has a strong patent portfolio and promising multiple products in the pipeline at various stages of development. The companys lead product RP5063 is a multimodal neuromodulator which has successfully completed the global Phase 2 clinical trials and has shown a superior efficacy and safety profile for schizophrenia and schizo affective disorder. After having a very successful End of Phase 2 ( EOP2 ) meeting with U.S. FDA, the company is now preparing to start the global Phase 3 clinical trials for RP5063 in acute and maintenance phase schizophrenia patients. The company is also planning to develop RP5063 for bipolar disorder, major depressive disorder (MDD), Alzheimers psychosis/agitation (ADP), Parkinsons psychosis (PDP), attention deficit hyperactivity disorder (ADD/ADHD) and autism spectrum.
Premium Sales Data for Prospecting
-
Sales data across over 200M records
-
Up-to-date records (less decayed data)
-
Accurate Email Lists (real-world tested)
-
Powerful search engine and intuitive interface
Get Full Access
Sign in to CIENCE GO Data to uncover contact details
Free credits every month